Sequence design and practical implementation of antisense oligonucleotides in neuroendocrinology

Methods in Enzymology

Volumn 314, Issue , 2000, Pages 223-238

  Neumann, Inga D ^a   Toschi, Nicola ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA;

BINDING KINETICS; DEGRADATION; IN VIVO STUDY; METHODOLOGY; NEUROENDOCRINOLOGY; NONHUMAN; NUCLEIC ACID PROBE; PRIORITY JOURNAL; REVIEW; SUPRAOPTIC NUCLEUS; THALAMUS MIDLINE NUCLEUS;

EID: 0032748977     PISSN: 00766879     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0076-6879(99)14106-5     Document Type: Article

References (34)

1. M. McCarthy, in "Applied Antisense Oligonucleotide Technology" (S. A. Stein and A. M. Krieg, eds.), p. 83. Wiley-Liss, New York, 1998.
2. S. G. N. Grant, T. J. O'Dell, K. A. Karl, P. L. Stein, P. Soriano, and E. R. Kandel, Science 258, 1903 (1992).
3. E. Hummler, T. J. Cole., J. A. Blendy, R. Ganss, A. Aguzzi, W. Schmid, F. Beermann, and G. Schutz, Proc. Natl. Acad. Sci. U.S.A. 91, 5647 (1994).
4. J. J. Zhao and G. Lemke, Mol. Cell. Neurosci. 11(1-2), 92 (1998).
5. A. Calogero, G. A. P. Hospers, and N. H. Mulder, Pharmacy World Sci. 19(6), 264 (1997).
6. N. Breton, C. Jacob, and P. Daegelen, J. Biomol. Struct. Dynam. 14(6), 727 (1997).
7. O. C. Uhlenbeck, A. Pardi, and J. Feigon, Cell 90, 833 (1997).
8. J. A. Doudna and E. A. Doherty, (1998). Folding Design 2(5), R65 (1998).
9. M. Zuker and D. Sankoff, Bull. Math. Biol. 46, 591 (1984).
10. F. H. D. Van Batenburg, A. P. Gultyaev, and C. W. A. Pleij, J. Theor. Biol. 174 (1995).
11. R. Lück, G. Steger, and D. Riesner, J Mol. Biol. 258, 3 (1996).
12. R. Landgraf, R. Gerstberger, A. Montkowski, J. C. Probst, C. T. Wotjak, F. Holsboer, and M. Engelmann, J. Neurosci. 15(5), 4250 (1995).
13. G. Liebsch, R. Landgraf, R. Gerstberger, J. C. Probst, C. T. Wotjak, M. Engelmann, F. Holsboer, and A. Montkowski, Regul. Pept. 59, 229 (1995).
14. B. Weiss, G. Davidkova, and S. P. Zhang, Neurochem. Int. 31(3), 321 (1998).
15. I. Neumann, Neurochem. Int. 31, 363 (1997).
16. J. F. Milligan, M. D. Matteucci, and J. C. Martin, Biochem. Soc. Trans. 24, 630 (1997).
17. A. K. Dutt and A. Datta, J. Phys. Chem. 102(41), 7981 (1998).
18. D. A. Fennell, Antisense Nucleic Acid Drug Dev. 6, 49 (1997).
19. I. D. Neumann and Q. J. Pittman, in "Modulating Gene Expression by Antisense Oligonucleotides to Understand Neuronal Functioning" (M. M. McCarthy, ed.), p. 43. Kluwer Publishing, Boston, 1999.
20. I. D. Neumann, D. W. F. Porter, R. Landgraf, and Q. J. Pittman, Am. J. Physiol. 267, R852 (1994).
21. I. Neumann, P. Kremarik, and Q. J. Pittman, Neuroscience 69(4), 997 (1995).
22. M. McCarthy, S. P. Kleopoulos, C. V. Mobbs, and D. W. Pfaff, Neuroendocrinology 59, 2 (1994).
23. A. Akabayashi, C. Wahlestedt, J. T. Alexander, and S. F. Leibowitz, Mol. Brain Res. 21, 55 (1994).
24. C. Wahlestedt, E. Merlo Pich, G. F. Koob, F. Yee, and M. Heilig, Science 259, 528 (1993).
25. K. M. Standifer, C. C. Chien, C. Wahlestedt, G. P. Brown, and G. W. Pasternak, Neuron 12, 805 (1994).
26. U. M. Sarmiento, J. R. Perez, J. M. Becker, and R. Narayanan, Antisense Res. Dev. 4, 99 (1994).
27. B. Schöbitz, G. Pezeshki, J. C. Probst, J. M. H. N. Reul, T. Skutella, T. Stöhr, F. Holsboer, and R. Spanagel, Europ. J. Pharm. 331 (1997).
28. J. F. Morris, D. V. Pow, H. A. Sokol, and A. Ward, in "Vasopressin" (P. Gross, D. Richter, and G. L. Robertson, eds.), p. 171 John Libbey, London, 1993.
29. I. Neumann, M. Ludwig, M. Engelmann, Q. P. Pittman, and R. Landgraf, Neuroendocrinology 58, 637 (1993).
30. C. T. Wotjak, J. Ganster, G. Kohl, F. Holsboer, R. Landgraf, and M. Engelmann, Neuroscience 85(4), 1209 (1998).
31. R. Landgraf, J. Neuroendocrinol. 7, 243 (1995).
32. I. Neumann, Q. J. Pittman, and R. Landgraf, in "Oxytocin" (R. Ivell and J. A. Russell, eds.), p. 173. Plenum Press, New York, 1995.
33. D. A. Clemett, M. I. Cockett, C. A. Marsden, and K. C. F. Fone, J. Neurochem. 71, 1271 (1998).
34. R. Landgraf, T. Naruo, M. Vecsernyes, and I. Neumann, Eur. J. Endocrinol. 137, 326 (1997).